Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Ublituximab in Relapsing Multiple Sclerosis
2019-003625-16Phase 3Active
- Sponsor
- TG Therapeutics, Inc.
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ublituximab in multiple sclerosis (MS), sponsored by TG Therapeutics, Inc. Primary endpoints: Long-term safety of ublituximab and Long-term efficacy of ublituximab. Started Mar 2020; status: active.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-003625-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003625-16.